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Abstract
Accumulation of amyloid-b (Ab) peptides in the brain is one of the central pathogenic events in Alzheimer’s disease (AD).
However, why and how Ab aggregates within the brain of AD patients remains elusive. Previously, we demonstrated
hemoglobin (Hb) binds to Ab and co-localizes with the plaque and vascular amyloid deposits in post-mortem AD brains. In
this study, we further characterize the interactions between Hb and Ab in vitro and in vivo and report the following
observations: 1) the binding of Hb to Ab required iron-containing heme; 2) other heme-containing proteins, such as
myoglobin and cytochrome C, also bound to Ab; 3) hemin-induced cytotoxicity was reduced in neuroblastoma cells by low
levels of Ab; 4) Hb was detected in neurons and glial cells of post-mortem AD brains and was up-regulated in aging and
APP/PS1 transgenic mice; 5) microinjection of human Hb into the dorsal hippocampi of the APP/PS1 transgenic mice
induced the formation of an envelope-like structure composed of Ab surrounding the Hb droplets. Our results reveal an
enhanced endogenous expression of Hb in aging brain cells, probably serving as a compensatory mechanism against
hypoxia. In addition, Ab binds to Hb and other hemoproteins via the iron-containing heme moiety, thereby reducing Hb/
heme/iron-induced cytotoxicity. As some of the brain Hb could be derived from the peripheral circulation due to a
compromised blood-brain barrier frequently observed in aged and AD brains, our work also suggests the genesis of some
plaques may be a consequence of sustained amyloid accretion at sites of vascular injury.
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Introduction
Alzheimer’s disease (AD) is characterized pathologically by the
presence of a large number of intraneuronal neurofibrillary
tangles, extracellular amyloid plaques and cerebral amyloid
angiopathy together with the loss of synapses. The main
component of the amyloid plaques and cerebral amyloid
angiopathy is the amyloid-b (Ab) peptide, derived from a larger
amyloid precursor protein (APP), by the proteolytic actions of b-
secretase and c-secretase [1,2]. Neuronal injury (e.g. dystrophic
neurites and synaptic loss) and microglia activation in the vicinity
of amyloid plaques led to the proposition of the amyloid cascade
hypothesis– profuse accumulation of soluble and insoluble forms of
Ab as the major cause of dementia [3,4]. This tenet was reinforced
by the engineering of APP transgenic mice and the discovery of
early-onset familial forms of AD [3,4]. The neurotoxicity of certain
aggregated forms of Ab (e.g. oligomeric and protofibrillar) further
strengthens the view of Ab as a key AD culprit [5–8].
Although extensive investigations have been implemented, the
mechanism for the abnormal accumulation and deposition of Ab
peptides in the majority of sporadic late-onset AD brains remains
unclear. Soluble forms of Ab exist in normal human brains and
CSF [9,10] and except for a few familial AD cases, the expression
of APP and production of Ab are not increased in most sporadic
AD patients [11–13]. In contrast, hypoxic/ischemic conditions
and traumatic brain injuries up-regulate APP mRNA and protein
[14–17] suggesting potential physiological roles for APP and/or
Ab. Furthermore, numerous molecules are known to interact with
Ab and alter the folding, stability and transport/clearance of these
peptides [18–22].
We and others have shown that hemoglobin (Hb) binds to Ab
and co-localizes in amyloid plaques and cerebral amyloid
angiopathy in AD brains [23,24]. However, the mechanisms for
the interaction between Ab and Hb and the potential roles of such
interaction remain unclear. In this study, we initially characterized
the binding between Ab and Hb by incubating Ab with different
components of Hb: 1) apohemoglobin (apoHb) or heme-free Hb,
2) heme and 3) protoporphyrin IX (PpIX) ring or iron-free heme.
In addition, the independent neurotoxicity of heme and Ab or a
mixture of both molecules was examined in vitro. The expression
patterns of Hb in the brains of APP/PS1 transgenic (tg) mice and
post-mortem AD patients were also assessed. Finally, the in vivo
interaction between Hb and Ab was studied by injection of Hb
into the hippocampi of APP/PS1 tg mice.
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Interaction between Hb and Ab
To demonstrate the interaction between Hb and Ab, equal
masses of Hb and Ab were incubated at 37uC for 0, 1, 3 and 7 d.
Western blotting revealed that, under reducing condition, freshly
dissolved Ab1–40 primarily migrated as 4 kDa monomers, 8 kDa
dimers and 12–16 kDa trimers/tetramers (Fig. 1A, left panel);
whereas, freshly prepared Ab1–42 was readily aggregated at the
start of incubation and formed smear signals between 4,12 kDa
and large oligomers around 48–96 kDa (Fig. 1B, left panel). The
amount of Ab1–40 oligomers (Fig. 1A, left panels) and Ab1–42
oligomers (Fig. 1B, left panels) increased as incubation time
increased. Hb, a 64 kDa tetramer with two 16 kDa each of Hb-a
and Hb-b subunits, was dissociated into 16 kDa monomers,
32 kDa dimers and 48 kDa trimers (Fig. 1, right panels). When Hb
co-incubated with Ab, large Ab
+ (Fig. 1, left panels) and Hb
+
(Fig. 1, right panels) aggregates were evident. Among the large
aggregates, discrete bands corresponded to Hb monomer and Ab
monomer (20 kDa), Hb monomer and Ab dimer (24 kDa), Hb
dimer and Ab monomer (36 kDa) and Hb dimer and Ab dimer
(40 kDa) were noticed (Fig. 1). These results suggest that Hb binds
to Ab and enhances its aggregation.
Heme is the critical Ab binding moiety of Hb
To characterize the Ab binding domains of Hb, we separated
the Hb into apoHb and heme. Our results showed that the discrete
Ab
+ bands (Hb/Ab complexes at 20, 24, 36 kDa, etc.) induced by
Hb were greatly reduced when Hb was replaced by apoHb
(Fig. 2A), suggesting the critical role of heme in the Hb-Ab
binding. As heme is a prosthetic group that consists of an iron
contained in the center porphyrin, we then examined the effects of
iron-free protoporphyrin IX (PpIX, porphyrin ring form of Hb-
heme) and iron-containing hemin (the ferric salt of heme) on Ab
aggregation. As shown in Figure 2A, hemin effectively facilitated
the formation of small Ab oligomers, while iron-free PpIX lost the
ability to interact with Ab. The interaction of hemin and Ab was
further evaluated in dose- and time- dependent fashions. When a
constant level of Ab was incubated with various concentrations of
hemin, the levels of SDS-stable Ab dimers, trimers and tetramers
increased as the amount of hemin increased (Fig. 2B). Similar
results were obtained when the level of hemin was kept constant
and the levels of Ab were increased (data not shown). The
formation of hemin-promoted Ab aggregations was also increased
as incubation time prolonged (Fig. 2C).
We were also interested in the Ab-binding activity of other
heme-containing hemoproteins. We chose myoglobin (MyoG) and
Figure 1. Interaction between hemoglobin (Hb) and Ab. Freshly dissolved Ab peptides (50 mM) were incubated with an equal mass of Hb
(3.5 mM) at 37uC for 0, 1, 3 and 7 d. A)A b1–40; B)A b1–42. Left panels, anti-Ab; right panels, anti-Hb-b chain.
doi:10.1371/journal.pone.0033120.g001
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while CytoC contains heme C. Heme C differs from heme B in
that the two vinyl side chains are covalently bound to the
apoprotein through thioether linkages, whereas heme B is attached
to the surrounding apoprotein through a single coordination bond
between the heme iron and an amino acid side chain [25]. Our
results showed that, in addition to Hb, both MyoG and CytoC
interacted and formed larger complexes with Ab (Fig. 2D).
We then examined the effects of hemin on the neurotoxicity of
Ab or vice versa on human neuroblastoma SH-SY5Y cells because
both molecules are known to cause neuronal death. In our
experimental settings, the LD50 of Ab1–42 was approximately
1 mM (Fig. 3A), while the LD50 of hemin was about 10 mM
(Fig. 3B). The presence of 2.5 mM of hemin, a concentration with
no overt cytotoxicity, did not alter the LD50 of Ab1–42 (Fig. 3A).
On the contrary, 0.25 mMo fA b1–42 reduced the cytotoxicity of
hemin at high levels (Fig. 3B). Two-way ANOVA indicated that
there were significant effects of hemin doses (F=40.3, d.f. 5/48,
p,0.001) and Ab (F=10.4, d.f. 1/48, p=0.002) on the hemin-
induced cytotoxicity. A significant interaction was evident
suggesting that the hemin-induced cytotoxicity was influenced by
Ab. The protective effect disappeared when Ab1–42 was replaced
by an equal amount of a peptide composed of the reverse Ab
sequence (Ab40-1, F=1.2, d.f. 1/36, p=0.272).
Aging and APP/PS1 transgenes increase the levels of Hb
in brain
The effects of age on the expression of Hb in the brains were
determined in APP/PS1 tg mice and their wild type (wt)
littermates. Because the deposition of amyloid plaques in the
APP/PS1 tg mice occurs around 6 months of age, we divided the
mice into two age groups: ,5 and .8 months. As shown in
Figure 4A, the intensities of Hb-b
+ signal were highest in the old
APP/PS1 tg mice. We quantified the intensities of Hb-b
+ signal in
primary motor cortex (part of frontal cortex), hippocampus and
entorhinal cortex (part of temporal cortex) because of their
intimate associations with AD pathologies [26]. Two-way
ANOVA indicated that there were significant effects of the
APP/PS1 transgenes on the intensities of Hb-b
+ signal in the
primary motor (Fig. 4B, F=5.0, d.f. 1/25, p=0.035) and
entorhinal cortices (Fig. 4B, F=5.4, d.f. 1/25, p=0.028); a
marginal effect in the hippocampus was also evident (Fig. 4B,
F=3.7, d.f. 1/25, p=0.065). Furthermore, the age of the mice also
increased the intensities of Hb-b
+ signal in the hippocampus
(Fig. 4B, middle panel; F=15.6, d.f. 1/25, p,0.001), although
such effect was not presented in the primary motor (p=0.108) and
entorhinal cortices (p=0.233).
The levels of Hb were also quantified using immunoblotting
analyses. As in the in vitro study shown in Figure 1, brain-derived
Hb was also resolved as monomer, dimer, trimer and tetramer
under denaturing conditions. This finding suggests that at least
some of the brain Hb proteins are in their mature form. As the
monomer band was predominant, we only quantified the relative
band density of this form of Hb (Fig. 5, upper panels). The levels of
Hb-a were up-regulated in the hippocampus, but not in the
cortex, of the APP/PS1 tg mice relative to the wt mice (Fig. 5A,
Two-way ANOVA, Cortex: F=2.0, d.f. 1/25, p=0.175; Hippo-
campus: F=11.6, d.f. 1/25, p=0.002). A similar effects of APP/
PS1 tg on Hb-b were also evident (Fig. 5B, Cortex: F=0.2, d.f. 1/
25, p.0.5; Hippocampus: F=4.3, d.f. 1/25, p=0.049). Further-
more, the levels of Hb in the hippocampus, but not cortex, were
also affected by age (Fig. 5; Two-way ANOVA, Hb-a: F=4.4, d.f.
1/25, p=0.047; Hb-b: F=5.2, d.f. 1/25, p=0.032). There was no
significant interaction between age and the two brain regions.
These results indicated that Hb was up-regulated by age and the
overexpression of APP/PS1 genes.
Localization of Hb in brains
While scrutinizing the brains of APP/PS1 tg mice, we found
that Hb-b antibodies stained numerous plaque-like structures and
cells (Fig. 4A, insert). These observations led us to investigate the
distribution and localization of Hb in brains. We examined the
expression of Hb in the brains of APP/PS1 tg mice because, under
the control of prion promoter, neurons of the APP/PS1 tg mice
Figure 2. Heme is the Ab binding moiety of hemoglobin (Hb).
A) Interactions between Ab and various part of Hb. B) Hemin induced
the Ab oligomerization in a dose-dependent fashion. C) Hemin induced
the Ab oligomerization in a time-dependent fashion. Incubation times:
0, 6, 24 hours. D)A b binds to Hb, myoglobin (MyoG) and cytochrome C
(CytoC).
doi:10.1371/journal.pone.0033120.g002
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[27]. Double immunofluorescence revealed that, in the cortex and
hippocampus of the APP/PS1 tg mice, the Hb-b
+ plaque-like
structures co-localized with Ab
+ amyloid plaques (Fig. 6).
Furthermore, Hb-b was expressed not only in the APP
+/Ab
+
neurons, but also in the cells without Ab accumulation (Fig. 6,
arrowheads in right enlarged panels). Conversely, we have also
noticed that some neurons expressed abundant APP/Ab in the
cytoplasm, yet no or little Hb signal was detected (Fig. 6, arrows in
right enlarged panels).
Figure 3. Effects of Ab on hemin induced cytotoxicity. A) Differentiated neuroblastoma cells, SH-SY5Y, were treated with different doses of
pre-incubated Ab1–42 without (open bars) or with 0.25 mM of hemin (closed bars). B) Differentiated SH-SY5Y cells were treated with different doses of
hemin without (open bars) or with 0.25 mM of pre-incubated Ab1–42 (closed bars). The cell viability was determined by MTT reduction assay.
Bonferroni’s post-hoc test: * p,0.05 vs. respective hemin group.
doi:10.1371/journal.pone.0033120.g003
Figure 4. The expression of hemoglobin (Hb) in APP/PS1 transgenic (Tg) mice and wild-type (Wt) littermates. A) Representative
immuno-micrographs reveal the intensities of Hb-b
+ stains in the coronal brain sections of a 3-month-old and a 14-month-old Tg and Wt mice,
respectively. Insert: enlarged micrograph shows the presence of Hb-b
+ stains in a plaque-like structure and some brain cells. B) Quantitative results of
the optical densities of Hb-b
+ stains in primary motor, hippocampus and entorhinal cortex of ,5-month-old and .8-month-old Tg and Wt mice.
Bonferroni’s post-hoc test: * p,0.05 vs. respective Wt group; # p,0.05, ## p,0.01 vs. respective ,5-month-old group.
doi:10.1371/journal.pone.0033120.g004
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immunstained human postmortem brain slices with Hb antibodies
and neuron (NeuN) or glia markers (oligodendrocyte: OSP,
astrocyte: GFAP, microglia: Iba-1). Hb immunoreactivities were
evident in a subpopulation of hippocampal and cortical neurons
(Fig. 7). Furthermore, almost all the OSP
+ oligodendrocytes were
Hb-b
+ (Fig. 7). In contrast, very few GFAP
+ astrocytes and Iba-1
+
microglia stained positive with Hb antibody (Fig. 7).
Ab surrounds the Hb in the brain
To investigate the interaction between Hb and Ab in vivo, we
microinjected human Hb (1 ml, 50 mg/ml) into dorsal hippocampus
of 4-month-old APP/PS1 tg mice. One week after the injection,
we found that Ab accumulated in the Hb injection site with Hb
droplets in the center and Ab surrounded in the periphery (Fig. 8).
A similar effect was also evident in the saline-injected hippocam-
pus of the APP/PS1 tg mice (Fig. 8), as microinjection inevitably
induced a variable degree of hemorrhage along the needle track.
We were unable to distinguish the patterns of Ab accumulation
around the injected human Hb from the injection-induced leakage
of mouse Hb. This effect was not observed in wt littermates (Fig. 8).
Discussion
In previous studies, we and others have identified human Hb as
a potent Ab-binding protein in the brain [23]. Further, we showed
that Hb co-localized with Ab in amyloid plaques and the cerebral
amyloid angiopathy of post-mortem AD brains. In this study, we
found that the interaction between Hb and Ab was heme
dependent. Other heme-containing proteins, such as myoglobin
and cytochrome C, also interacted with Ab. The iron atom within
the protoporphyrin IX was indispensable for the binding of heme
to Ab. Heme-induced cytotoxicity was reduced by Ab, presumably
by the Ab-iron interaction. Hb was present in amyloid plaques and
brain cells, mainly in neurons and oligodendrocytes. Furthermore,
the levels of Hb increased in aging and APP/PS1 tg mice. Finally,
we showed that injection of exogenous human Hb into the brains
of APP/PS1 tg mice induced Ab accumulation at the site of Hb
deposition.
Hemoglobin is expressed in specific brain cells and the
expression levels of brain Hb increased with age in APP/PS1 tg
mice. The presence of Hb-a and Hb-b mRNAs in brains was
initially reported by Ono and Cutler more than three decades ago
[28]. They found that both the levels of Hb-a and Hb-b mRNA
were elevated in the cytoplasm of aged brain cells in rats [28]. The
presence of Hb mRNA in brain tissue has been confirmed in
rodents and humans [23,29–32]. Interestingly, the levels of Hb
were not only positively correlated with age in rats, but negatively
correlated to their learning and memory performances [29].
Hemoglobin proteins and Hb-derived peptides have been isolated
from human CSF and brain tissues using different biochemical
techniques [24,33–36]. The expression of Hb mRNA was evident
in the neurons of rat cortex, hippocampus and substantia nigra by
Figure 5. The levels of hemoglobin (Hb)-a and Hb-b in ,5-
month-old and .8-month-old APP/PS1 transgenic (Tg) mice
and wild-type (Wt) littermates. Representative immunoblots are
shown on the top of each panel whereas quantitative results are shown
in the respective lower panel. The levels of Hb monomer (,16 kDa) are
quantified by immunoblotting analyses. Bonferroni’s post-hoc test:
* p,0.05, ** p,0.01, vs. respective Wt group; ## p,0.01 vs. respective
,5-month-old group.
doi:10.1371/journal.pone.0033120.g005
Figure 6. Localization of hemoglobin (Hb) immunoreactivity in
brains of APP/PS1 transgenic (Tg) mice. Double immunofluores-
cent micrographs reveal the presence of Hb-b
+ stains in Ab
+ amyloid
plaques and some brain cells. Scale bars: 50 mm. Examples of enlarged
micrographs are shown in the right. Arrowheads point to Hb-b
+, but
APP/Ab
2 cells; while, arrows show APP/Ab
+, but Hb-b
2 cells.
doi:10.1371/journal.pone.0033120.g006
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immunohistochemical staining of Hb in the neurons of human and
rodent brains [23,31,32,34]. The expressions of Hb in oligoden-
drocytes and astrocytes have also been documented previously, but
with some controversy [31,37,38]. Taken together, these findings
demonstrate that Hb is expressed in brain cells and that the levels
of brain Hb increase with age.
The levels of Hb were also elevated in the brains of AD patients.
In a previous publication, we have shown that both the Hb mRNA
and protein levels were up-regulated in the AD brains, with the
levels of Hb highest in the hippocampus and cortical gray matter,
followed by white matter and the lowest in cerebellum [23]. We
have also shown that 64% to 96% of amyloid plaques and almost
all the cerebral amyloid angiopathy were positively stained for Hb
[23]. In this study, we further confirm that Hb is present in the
extracellular amyloid plaques and cytoplasm of brain cells. Using
proteomic approaches, elevated Hb levels were found in temporal
and sensorimotor cortices and CSF of AD patients [35,36].
Exogenous Hb released from red blood cells after traumatic
brain injury or intracerebral hemorrhage is highly neurotoxic
[39,40]. However, recent evidence indicates that enhanced
expression of intracellular globins, such as neuroglobin [41–43]
and haptoglobin [44], protects neurons against hypoxic-ischemic
injury. Considering that: 1) Hb is the most abundant oxygen-
carrier protein in the human body, 2) the gene expression of Hb is
regulated by hypoxia-inducible factor 1a [45] and 3) cerebral
hypoperfusion is frequently observed in aged brains [46], it is
possible that an up-regulation of Hb during aging is a feedback
response to hypoxia. Indeed, enhanced Hb expression in neurons
has been demonstrated to be regulated by hypoxia-stimulated
erythropoietinin in rodents [38]. Furthermore, Ab is also known to
increase vascoconstriction and decrease cerebral blood flow
[47,48]. Aging associated hypoperfusion and increased Ab could
stimulate the production of an intracellular pool of Hb that may
serve as an oxygen reservoir during periods of increased oxygen
demand [38].
A portion of the brain Hb may be derived from the transient
extravasation of erythrocytes or free-Hb in the neuropil originating
from the peripheral circulation. Accumulating evidence indicates
that aging and AD are associated with profound changes in blood-
brain barrier structure and function [46,49,50]. In addition,
cerebrovascular diseases commonly observed in AD, including
cerebral amyloid angiopathy, microvascular degeneration (capil-
lary tortuosity, string vessels, vascular fibrohyalinosis and lipohya-
Figure 7. The distribution of hemoglobin (Hb) immunoreactivity in inferior temporal gyrus of post-mortem human brain. Hb-b
+
stains are present in most NeuN
+ neurons and OSP
+ oligodendrocytes; while only a small fractions of GFAP
+ astrocytes and Iba-1
+ microglia express
Hb. Scale bars: 10 mm.
doi:10.1371/journal.pone.0033120.g007
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are known to disturb the integrity of cerebral vessels and alter
brain perfusion [51–54].
In this study, we also demonstrate that the iron-containing heme
group is critical for Ab binding to Hb. The binding of Ab to heme
has been previously characterized by Atamna’s group [55,56]. In
addition, we found that other heme-containing proteins were
likewise capable of interacting with Ab, reinforcing the view that
the iron-containing heme group mediates the interaction between
Ab and hemoproteins. Hb and other hemoproteins are potentially
hazardous because their iron-containing heme can trigger a
Fenton reaction capable of catalyzing the generation of the
hydroxyl-radical [40,57]. High levels of Ab, especially the
oligomeric forms, are also known to be neurotoxic in vitro [5–
8]. However, the Ab-induced neurotoxicity was not recaptured in
most in vivo studies by directly injecting Ab into the living brain
[58–61]. Surprisingly, while iron has been shown to aggravate the
neurotoxicity of high levels of Ab, iron-induced oxidation, lipid
peroxidation and neurotoxicity are blocked by Ab [58,62,63]. The
latter findings were supported by our observation that the
cytotoxicity of heme was reduced by applying a sublethal dose
of Ab to the culture. These findings also suggest that by virtue of
binding to Ab, the hemorrhage-associated Hb/heme toxicity can
be confined.
The interaction between Ab and Hb in vivo suggests that Ab
may act as a protective adhesive and that its continuous
accumulation may ultimately participate in the formation of
amyloid plaques and/or cerebral amyloid angiopathy. However,
as microinjection inevitably induced hemorrhage, we cannot
exclude the possibility that other molecules in the blood also
participate in the accumulation of Ab along the injection-induced
leakage. Formation of amyloid plaques at sites of capillary bleeding
was supported by the findings that every plaque in AD brain is
positive for Hb, heme, or vessel-derived proteins [64,65]. Detailed
analyses of these plaques have led to the conclusion that each
amyloid plaque is either in direct contact or closely related to a
small vessel [64–68]. Similarly, stereological analyses of APP tg
mice also suggest that leaky capillaries create a ‘nidus’ for plaque
formation [69–71]. The direct association of amyloid plaques with
the microvasculature was characterized by vascular corrosion casts
and scanning electron microscopic visualization of the entire brain
vasculature in APP tg mice [72]. In young APP tg mice, before
typical amyloid plaques appeared, microvascular alterations with
small amyloid deposits attached to the distorted vessels are present
[72]. In older APP tg mice and AD patients, some vessels are
truncated with their stumps terminating close to amyloid plaques
[64,72,73]. The putative leaking vessel-sealing function of Ab
could also explain why immediately after traumatic brain injury
the production of Ab is up-regulated [16,17]. Therefore, it is not
surprising that disruption of deposited Ab from the vasculature by
anti-Ab antibodies significantly increased the frequency of
intracerebral hemorrhage in APP tg mice [74]. As proposed
previously, Ab might form an intracranial ‘‘scab’’ maintaining the
structural integrity of cerebral vasculatures [71,75].
The idea that capillary hemorrhage is the key event in plaque
formation has been proposed previously [76]. In his excellent
review, Stone [76] provides rich pathological and epidemiological
evidence supporting the association between microhemorrhage
and amyloid deposition. Stone hypothesized that microhemor-
rhage-induced ischemia results in the production of Ab and that
the oligomerization of this molecule is elicited by blood
components, such as Hb. The Ab oligomers then assemble into
Figure 8. Hemoglobin (Hb) induces Ab accumulation in the immediate surroundings of Hb. Human Hb (1 ml, 50 mg/ml) was injected into
the dorsal hippocampus of 4-month-old APP/PS1 transgenic (Tg) mice. One week after the injection of Hb or saline, the brain sections were double
stained for Hb-b and Ab. Tg-negative: The sections were stained only by Hb antibodies, but not Ab antibodies and serve as negative controls for Ab
staining. Scale bars: 30 mm.
doi:10.1371/journal.pone.0033120.g008
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observations that Hb binds Ab and promotes the oligomerization
favor his premise. However, our data also suggest that instead of
inducing damage to neural tissues, sublethal Ab levels seem to play
a protective role in the early stages of hemorrhage. The associated
secondary injuries, i.e. inflammation and oxidative stress, emerge
at later chronic stages when the wound-healing scars gradually
evolve into mature amyloid plaques. In light of these observations,
we would like to propose the following scenario: 1) when
microhemorrhage occurs as the result of aging, traumatic brain
injury or cerebrovascular disease, Ab can act as a sealant
preventing further leakage of toxic blood components; 2) Ab
peptides aggregate around the leaked Hb limiting its toxicity; 3)
Ab binds to heme preventing the generation of toxic reactive
oxygen species and promoting heme degradation [55]; 4) Ab
chelates and sequesters free iron thereby greatly reducing direct
iron-elicited oxidative toxicity. Malfunction of the blood-brain
barrier is prevalent in aged individuals and the observed physical
proximity of plaques and capillaries suggests that some amyloid
deposits may result from the chronic accretion of Ab around sites
of vascular leakage or damage.
Materials and Methods
Materials
Recombinant Ab1–40 and Ab1–42 peptides were purchased from
rPeptide (Bogart, GA, USA). The composition and the purity of
the peptides were characterized by HPLC and mass spectrometry.
Human Hb, myoglobin, cytochrome C, hemin and PpIX were
purchased from Sigma-Aldrich (St. Louis, MO, USA). The
preparation and isolation of apoHb, the heme-free Hb, was
carried out using the acid-acetone method as previously described
[77]. HPLC-grade dimethyl sulfoxide (DMSO, 99.9%), Tris-HCl,
SDS and chloral hydrate were purchased from Sigma-Aldrich.
Binding Assay
Recombinant Ab1–40 or Ab1–42 powders (1 mg) were suspended
in 1 ml of 1% NH4OH and diluted in 50 mM of Tris-HCl,
pH 7.4, to make an Ab working solution of 100 mM. The Ab
working solution was incubated with an equal volume of Hb
solution (6.8 mM in DDH2O) and incubated at 37uC for 0, 1, 3
and 7 d. The final concentrations in the solution were 50 mM for
Ab and 3.5 mM for Hb (1:1 in weight ratio). Hemin (MW 651.9)
and PpIX (MW 562.7) were suspended in 100% DMSO (0.5 mg/
ml) and diluted in 50 mM of Tris-HCl, pH 7.4, to make the
desired amounts. After mixing with Ab peptides, the mixtures
were incubated at 37uC for 0, 6 or 24 h. At the end of the
incubation, 12 ml of the solutions were mixed with 4 mlo f4 6
sample buffer (Invitrogen, Carlsbad, CA, USA), heated to 70uC
for 10 min and resolved on a 4–12% Bis-Tris gel (Nu-PAGE,
Invitrogen). The resolved proteins were transferred onto nitrocel-
lulose membranes (GE Healthcare Bio-Sciences Corp., Piscat-
away, NJ, USA), briefly boiled in 50 mM Tris-HCl buffer, pH 7.4,
blocked with 5% non-fat milk, and probed with a mixture of anti-
Ab monoclonal antibodies (4G8, 1:10000; 6E10, 1:10000;
Covance, Princeton, NJ, USA). A parallel gel was used to probe
with anti-Hb-b chain goat polyclonal antibodies (M-19, Santa
Cruz Biotech.; 1:500).
Animals
All experiment protocols were carried out in accordance with
the National Institutes of Health Guidelines for animal research
(Guide for the Care and Use of Laboratory Animal) and approved
by the National Cheng Kung University Institutional Animal Care
and Use Committee. Male APP/PS1 double tg mice were
purchased from the Jackson Laboratory (Bar Harbor, ME) and
maintained in a controlled environment (temperature 2361uC;
12 h light/12 h dark cycle, light cycle begins at 06:00) of the
Laboratory Animal Center of National Cheng Kung University
with unrestricted access to food and water. The APP/PS1 double
tg mice express a chimeric mouse/human amyloid precursor
protein (Mo/HuAPP695swe) and a mutant human presenilin 1
(PS1-dE9) with the exon 9 deletion under the control of mouse
prion promoter elements. Shortly after weaning, these mice were
genotyped with PCR using a protocol provided by the Jackson
Laboratory.
Surgery
Male APP/PS1 tg mice at 4-month-old (20 g–25 g) were
anesthetized by 0.4 g/kg of chloral hydrate (Sigma) before the
procedure. The mouse skull was mounted on a stereotactic
apparatus (Stoelting Co., IL) and a midline incision of the scalp
was done to expose the skull. The microinjection was performed at
the dorsal hippocampus (stereotaxic coordinates (mm from
bregma): anterior/posterior, -1.7; lateral, 1.2; dorsoventral, 1.3)
using a 29-gauge needle attached to a 10-ml syringe. One mlo fH b
(50 mg/ml) was injected and the injection rate was set at 0.2 ml/
min. An equal amount of normal saline was infused to serve as
control. The needle was removed 5 min after the completion of
injection.
Tissue preparations
After deep anesthesia, mice were intracardially perfused with
paraformaldehyde and their brains were removed, post-fixed and
sliced at 30 mm as previously described [78]. Coronal sections
were collected in cryoprotectant and stored at 220uC. For
biochemical analyses, freshly removed brains were dissected and
rapidly submerged in liquid nitrogen for 10 min before storage at
270uC. The paraformaldehyde fixed, free floating frozen sections
(40 mm in thickness) prepared from the right temporal lobe and
associated cortex from both AD and ND individuals were kindly
provided by Dr. Tom Beach (Brain Bank of the Banner Sun
Health Research Institute, Sun City, AZ, USA).
Immunohistochemistry
The paraformaldehyde-fixed brain sections were preblocked in
5% normal rabbit serum (Vector Laboratories, Burlingame, CA)
and stained with anti-hAPP mouse monoclonal antibodies (2C12,
Sigma; 1:500), anti-Ab mouse monoclonal antibodies (4G8; 1:500)
or anti-Hb-b goat polyclonal antibodies (M-19; 1:500). The
specificity of the Hb antibody has been demonstrated previously
by pre-absorption with Hb in human brain sections [23]. The
brain sections were then incubated with appropriate peroxidase-
conjugated secondary antibodies and an avidin-biotin peroxidase
(Vectastain Elite ABC kit, Vector) using 3,39-diaminobenzidine as
the substrate.
Immunofluorescence
For immunofluorescence double labeling, free-floating tissues
were washed three times in PBS with 0.5% Triton X-100 and
stained for Hb-b (M-19; 1:250), Ab (4G8; 1:250), NeuN (Millipore,
Billerica, MA; 1:500), OSP (Abcam, Acmbridge, MA; 1:500),
GFAP (Dako, Glostrup, Denmark; 1:500) and Iba-1 (Wako,
Osaka, Japan; 1:500) antibodies overnight at 4uC. For detection of
primary antibodies, fluorescein Alexa488-conjugated anti-goat
(Invitrogen; 1:1000), FITC-conjugated (Jackson ImmunoRe-
search, West Grove, PA; 1:1000) anti-mouse, Rhodamine-
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biotin-conjugated anti-goat (Jackson ImmunoResearch; 1:1000)
secondary antibody was used according to the instructions from
the manufacturer. Control sections were treated identically except
that the primary antibody was omitted. Coverslips were mounted
in 2.6% DABCO (Sigma) in 90% glycerol/10% PBS and imaged
with a Zeiss fluorescent microscope.
Image analysis
To analyze the relative optical intensity of immunomicrographs,
the photomicrographs were taken by an Axiocam MRc digital
camera connected to a computer equipped with Axiovision 4.8
software (Carl Zeiss, Inc., Thornwood, NY). Signal relative
intensities were obtained by dividing the optical densities of the
desired brain regions to that of backgrounds of each section using
the ImagePro plus 6.0 software (Bethesda, MD). The optical
density of an area in the corpus callosum free of any signal was
designed as background reading.
Neurotoxicity assay
The human neuroblastoma SH-SY5Y cells were cultured in
DMEM/F12 medium (Invitrogen) supplemented with 10% fetal
bovine serum, 1% L-glutamine and 1% penicillin/Streptomycin.
Cells were grown in a humidified atmosphere of 5% CO2 and
95% air at 37uC. Three days before treatment, 1610
4 cells were
seeded in 96-well plates and differentiation was induced by
10
25 M retinoic acid in 200 ml serum-free DMEM media. The
survival rates of the cells were determined by the MTT, 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetraolium bromide (Sigma),
reduction assay. Ab1–42, dissolved in 1% NH4OH and diluted in
Tris-HCl as described above (Binding Assay section), was
incubated at 37uC for 24 h before treating the cells. Hemin was
prepared as aforementioned. After treating the differentiated SH-
SY5Y cells with different concentrations of Ab1–42, hemin or a
mixture of Ab1–42 and hemin for 48 h, 50 ml of MTT solution was
added to each well for 4 h, followed by adding another 50 mlo f
DMSO per well with dark incubation for 20 min. Absorbency was
measured by a spectrophotometer at wavelength of 595 nm.
Statistics
Data were expressed as mean 6 S.E.M. Two-way analysis of
variance followed by Bonferroni posttest was used to analyze the
results of Hb expression levels in brains with the APP/PS1
transgenes as within-subject factor and age as between-subject
factor. The animal number used in each group was indicated by n.
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